The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Neuroprotective Effects of Resveratrol Against Aβ Administration in Rats are Improved by Lipid-Core Nanocapsules
Open accessAbstract
Alzheimer's disease (AD), a neurodegenerative disorder exhibiting a gradual decline in cognitive function, is characterized by the presence of neuritic plaques composed of neurofibrillary tangles and amyloid-β (Aβ) peptide. Available drugs for AD therapy have small effect sizes and do not alter disease progression. Several studies have been shown that resveratrol is associated with anti-amyloidogenic properties, but therapeutic application of its beneficial effects is limited. Here we compared the neuroprotective effects of free resveratrol treatment with those of resveratrol-loaded lipid-core nanocapsule treatment against intracerebroventricular injection of Aβ1-42 in rats. Animals received a single intracerebroventricular injection of Aβ1-42 (2 nmol), and 1 day after Aβ infusion, they were administered either free resveratrol (RSV) or resveratrol-loaded lipid-core nanocapsules (5 mg/kg, each 12 h, intraperitoneally), for 14 days. Aβ1-42-infused animals showed a significant impairment on learning memory ability, which was paralleled by a significant decrease in hippocampal synaptophysin levels. Furthermore, animals exhibited activated astrocytes and microglial cells, as well as disturbance in c-Jun N-terminal kinase (JNK) and glycogen synthase kinase-3β (GSK-3β) activation, beyond destabilization of β-catenin levels. Our results clearly show that by using lipid-core nanocapsules, resveratrol was able to rescue the deleterious effects of Aβ1-42 while treatment with RSV presented only partial beneficial effects. These findings might be explained by the robust increase of resveratrol concentration in the brain tissue achieved by lipid-core nanocapsules. Our data not only confirm the potential of resveratrol in treating AD but also offer an effective way to improve the efficiency of resveratrol through the use of nanodrug delivery systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An in vivo study suggested that resveratrol-encapsulated lipid core nanocapsules are highly effective against Aβ-induced neurotoxicity.”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [111]
In the citing paper
“The promising improvement in short-term and long-term memory was attributed to the higher bioavailability of resveratrol in the brain.111”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [111]
Citations
Cites
The rat brain in stereotaxic coordinates
Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,959
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data
Ennaceur, A., & Delacour, J. (1988) · Behavioural Brain Research · doi:10.1016/0166-4328(88)90157-x · Cited by 3,223
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Wnt signaling: a common theme in animal development
Cadigan, K. M., & Nusse, R. (1997) · Genes & Development · doi:10.1101/gad.11.24.3286 · Cited by 2,567
Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism
Liu, C., Li, Y., Semënov, M. V., Han, C., Baeg, G., Tan, Y., Zhang, Z., Lin, X., & He, X. (2002) · Cell · doi:10.1016/s0092-8674(02)00685-2 · Cited by 2,152
Cited by
Sorted by citations
Items 101–165 of 165
Zeini, S., Davoodian, N., Kazemi, H., Brojeni, M. S., Ghani, E., Firouzjaei, M. A., & Atashabparvar, A. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114508 · Cited by 19
Colloids for drug delivery to the brain
Santander-Ortega, M. J., Plaza-Oliver, M., Robledo, V. R., Castro‐Vázquez, L., Villaseca-González, N., González-Fuentes, J., Marcos, P., Jiménez, M. D. M. A., & Lozano, M. V. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.07.012 · Cited by 19
Nanomedicine against Alzheimer’s and Parkinson’s Disease
Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 20
Dai, D., He, L., Chen, Y., & Zhang, C. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.12.013 · Cited by 20
Mishra, K., Rana, R., Tripathi, S., Siddiqui, S., Yadav, P. K., Yadav, P. N., & Chourasia, M. K. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03955-3 · Cited by 18
Yokoyama, T., Suzuki, R., & Mizuguchi, M. (2020) · IUCrJ · doi:10.1107/s2052252520015614 · Cited by 18
Zancan, L. R., Bruinsmann, F. A., Paese, K., Türck, P., Bahr, A. C., Zimmer, A., Carraro, C. C., Schenkel, P. C., Belló‐Klein, A., Schwertz, C. I., et al. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121181 · Cited by 17
Self-citationAmino Acid-PEGylated Resveratrol and Its Influence on Solubility and the Controlled Release Behavior
Zhang, Y., Song, H., Shang, Z., Chen, A., Huang, D., Zhao, H., & Du, H. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00863 · Cited by 17
Wang, W., Liu, G., Jiang, X., & Wu, G.-M. (2021) · Birth Defects Research · doi:10.1002/bdr2.1962 · Cited by 16
Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
Kanubaddi, K. R., Yang, S.-H., Wu, L.-W., Lee, C., & Weng, C. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s179484 · Cited by 17
Baldissera, M. D., Souza, C. F., Silva, A. S. D., Velho, M. C., Ourique, A. F., & Baldisserotto, B. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.103989 · Cited by 16
Nanotechnology‐empowered therapeutics targeting neurodegenerative diseases
Wang, Z., Gonzalez, K. M., Cordova, L. E., & Lu, J. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1907 · Cited by 18
Yokoyama, T., Kusaka, K., Mizuguchi, M., Nabeshima, Y., & Fujiwara, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01698 · Cited by 15
Xia, H., Wu, L., Chu, M., Feng, H., Lu, C., Wang, Q., He, M.-H., & Ge, X. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.05.003 · Cited by 16
Alzheimer's Disease: Status of Low‐Dimensional Nanotherapeutic Materials
Huang, D., Liao, W., Li, J., Chen, T., Wang, X., Zhao, R., Zhang, L., Yu, X., Zheng, D., & Luan, P. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202302015 · Cited by 15
Drug Delivery to the brain: How Can Nanoencapsulated Statins Be Used in the Clinic?
Sonvico, F., Zimetti, F., Pohlmann, A. R., & Guterres, S. S. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0044 · Cited by 14
Self-citationResveratrol: Protective Agent Against Alzheimer’s Disease
Subhan, I., & Siddique, Y. H. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249287167240222081517 · Cited by 12
El-Sayed, S. A. M., Fouad, G., Rizk, M., Beherei, H., & Mabrouk, M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04415-x · Cited by 13
Polyphenols as Wnt/β‐catenin pathway modulators: A promising strategy in clinical neurodegeneration
Utpal, B. K., Roy, S. C., Zehravi, M., Sweilam, S. H., Raja, A. D., Haque, M. A., Nayak, C., Balakrishnan, S., Singh, L. P., Panigrahi, S., et al. (2025) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12525 · Cited by 12
de Andrade, D. F., Vukosavljević, B., Hoppe, J. B., Pohlmann, A. R., Guterres, S. S., Windbergs, M., Külkamp‐Guerreiro, I. C., Salbego, C. G., & Beck, R. C. R. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1501-1 · Cited by 12
Self-citationGiacomeli, R., Teixeira, F. E. G., de Carvalho, F. B., Pacheco, C. O., Parisotto, A. J. M., Ribeiro, A. C. F., de Gomes, M. G., & Haas, S. E. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111625 · Cited by 12
Acute Exposure of the Mediobasal Hypothalamus to Amyloid-β 25-35 Perturbs Hepatic Glucose Metabolism
Arrieta‐Cruz, I., Knight, C. M., & Juárez, R. G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-131865 · Cited by 10
Poddar, N. K., Agarwal, D., Agrawal, Y., Wijayasinghe, Y. S., Mukherjee, A., & Khan, S. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166524 · Cited by 10
Resveratrol’s bibliometric and visual analysis from 2014 to 2023
Wei, H., Fang, G., Song, W., Cao, H., Dong, R., & Huang, Y. (2024) · Frontiers in Plant Science · doi:10.3389/fpls.2024.1423323 · Cited by 9
Progress in the treatment of Alzheimer's disease based on nanosized traditional Chinese medicines
Song, D., Zhang, J., Hu, X., & Liu, X. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb02062f · Cited by 9
Encapsulation technologies for resveratrol in functional food
Chávarri, M., & Villarán, M. C. (2016) · doi:10.1002/9781119227625.ch8 · Cited by 9
Yokoyama, T., & Kusaka, K. (2023) · FEBS Journal · doi:10.1111/febs.16817 · Cited by 8
de Andrade, D. F., Vukosavljević, B., Benvenutti, E. V., Pohlmann, A. R., Guterres, S. S., Windbergs, M., & Beck, R. C. R. (2017) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2017.1400559 · Cited by 8
Self-citationAkkol, E. K., Karatoprak, G. Ş., Dumlupınar, B., Açıkara, Ö. B., Arıcı, R., Yücel, Ç., Aynal, L. C., & Sobarzo‐Sánchez, E. (2025) · Molecules · doi:10.3390/molecules30091982 · Cited by 8
Nagaraju, P. G., Ashwini, S., & G., P. P. C. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2092446 · Cited by 7
Lazarova, M. I., Stefanova, M. O., Tsvetanova, E. R., Georgieva, A. P., Tasheva, K. N., Radeva, L., & Yoncheva, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312777 · Cited by 8
Forouzanfar, F., Pourbagher‐Shahri, A. M., Vafaee, F., Sathyapalan, T., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230504121523 · Cited by 6
Ravi, S. K., Ramesh, B. N., Kj, S., Poyya, J., Karanth, J., Raju, N. G., & Joshi, C. G. (2022) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2021.2021749 · Cited by 6
Dhingra, A. K., Rathi, V. K., & Chopra, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819212-2.00037-2 · Cited by 6
Chowdhury, S., Kumari, G., & Jit, T. (2025) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2025.100249 · Cited by 5
Bridging the molecular and clinical aspects of resveratrol in Alzheimer’s disease: a review
Mathew, L. S., Marathe, A., Aman, A., Vats, A., Joy, T., & Rao, Y. L. (2025) · 3 Biotech · doi:10.1007/s13205-025-04451-x · Cited by 5
Huang, M., Sui, R., Zhang, L., Zhu, Y., Yuan, X., Jiang, H., & Mao, X. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01320-y · Cited by 4
The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity
Gerson, J. E., Cascio, F. L., & Kayed, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00006-5 · Cited by 4
Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment
Hernando, S., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-57696-1_3 · Cited by 4
Bio-nano Interface and Its Potential Application in Alzheimer’s Disease
Pradhan, B., Jit, B. P., Maharana, S., Ramchandani, S., & Jena, M. (2021) · Springer eBooks · doi:10.1007/978-981-16-2516-9_12 · Cited by 5
Wei, H., Zhang, G., Xu, Y., Zhao, A., Zheng, Y., Shao, Y. W., Yang, L., Wang, J., & Jiang, X. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157238 · Cited by 3
Petry, F. D. S., Hoppe, J. B., Klein, C. P., dos Santos, B. G., Hözer, R. M., Salbego, C. G., & Trindade, V. M. T. (2022) · Neurological Research · doi:10.1080/01616412.2021.2024731 · Cited by 3
Self-citationRumman, M., & Khan, M. V. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107767 · Cited by 2
Antioxidant Effect of Resveratrol and Its Control Effect on Related Diseases
张, 晓. (2017) · Hans Journal of Food and Nutrition Science · doi:10.12677/hjfns.2017.62006 · Cited by 2
Obulesu, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816412-9.00001-x · Cited by 3
Microglia-mediated neuroinflammation and Mediterranean diet
Ortega, R. H., de Pablos, R. M., Cerezo, A. B., Richard, T., García-Parrilla, M. C., & Troncoso, A. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818649-7.00031-x · Cited by 2
de Santana, T. S., Mafra, J. F., Ferreira, M. A., Bispo, A. S. D. R., Viana, E. D. S., Reis, R. C., Souza, B. C. D. O., & Evangelista-Barreto, N. S. (2024) · Journal of Aquatic Food Product Technology · doi:10.1080/10498850.2024.2305971 · Cited by 2
Update of Natural Compounds in Transthyretin Amyloidosis, Years 2020–2025
Marotta, C., Ciccone, L., & Nencetti, S. (2025) · Crystals · doi:10.3390/cryst15080696 · Cited by 1
Kim, W. S., Choi, J., Kim, S.-S., Kim, J. H., Han, Y., Ahn, M. J., Oh, S., Lee, B., Cho, I., Choi, C. W., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119019 · Cited by 1
Neuroprotection of Multitargeted Phytochemicals against Alzheimer: A Desperate Need from Nature
Dhingra, A. K., & Chopra, B. (2022) · The Natural Products Journal · doi:10.2174/2210315512666220627153553 · Cited by 1
Drug Delivery Strategies in Alzheimer’s Disease
Hake, G., Mhaske, A. S., & Shukla, R. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_12 · Cited by 1
Nanotechnological Applications in the Diagnosis and Treatment of Alzheimer’s Dementia
Singh, P. N. D., Mishra, G., Pottoo, F. H., Zeleke, M. M., & Ewunetei, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-7606-2_22 · Cited by 1
Prevention of Neuroinflammation by Resveratrol
Renaud, J., & Martinoli, M. (2017) · Wiley eBooks · doi:10.1002/9781119155195.ch18 · Cited by 1
Nanodelivery of Polyphenols as Nutraceuticals for CNS Disorders
Samaiya, P., Sagar, R., Pandey, S., Jain, G., & Sah, A. K. (2023) · doi:10.1002/9781394188864.ch11 · Cited by 1
Resveratrol in Experimental Models and Humans
Gambini, J., Gimeno-Mallench, L., Mas‐Bargues, C., Pérez-López, G., Borrás, C., & Viña, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00080-4
Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer’s Disease
Talegaonkar, S., Gautam, N., Varshney, V., Sharma, S., & Bhattacharyya, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_13
How Could QbD Address the R&D Challenges of ‘Nose-To-Brain’ Liposomal Resveratrol Formulations?
Németh, Z., Pallagi, E., Dobó, D. G., & Csóka, I. (2020) · International Electronic Conference on Pharmaceutics (IECP) · doi:10.3390/iecp2020-08661
Resveratrol and brain mitochondria
Coelho, P., & Rego, A. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821562-3.00018-6
Obulesu, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816412-9.00009-4
NANOCÁPSULAS DE NÚCLEO LIPÍDICO: PREPARAÇÃO, CARACTERIZAÇÃO E APLICAÇÕES BIOLÓGICAS
Dallemole, D. R., Ciocheta, T. M., Frank, L. A., Alves, A. D. C. S., Pacheco, B. Z., Guterres, S. S., Paese, K., & Pohlmann, A. R. (2023) · Química Nova · doi:10.21577/0100-4042.20230077
Self-citationRole of Co-Block Polymers in the Treatment of Neurodegenerative Diseases
Kaur, S., Ghosh, S., Sharma, G., Mishra, J., Joshi, R., Bhatti, G. K., & Bhatti, J. S. (2023) · Springer eBooks · doi:10.1007/978-981-99-6917-3_6
Natural antioxidant nanoparticles in neuroprotection
Hort, M. A., Vaz, G. R., Marques, M. D. S., Schimith, L. E., dos Santos, M. G., Arbo, B. D., Horn, A. P., & Dora, C. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00081-6
Alzheimer's disease – An overview of nano herbal formulations
Patil, V. S., Patil, S., Patil, S. R., Pawar, A. S., & Shete, A. S. (2025) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2025.100042
Kumar, A. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02417-w
Metadata
- Authors
- Frozza, R. L., Bernardi, A., Hoppe, J. B., Meneghetti, A. B., Matté, A., Battastini, A. M. O., Pohlmann, A. R., Guterres, S. S., & Salbego, C.
- Affiliations
- Universidade Federal do Rio Grande do Sul (BR)
- Corresponding author
- Frozza, Rudimar L.
- ORCID
- Venue
- Molecular Neurobiology
- Published
- 2013-01-12
- Volume
- 47
- Issue
- 3
- Pages
- 1066-1080
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W2037132719
- Cited by
- 165
- References
- 81
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 10 · 2023: 17 · 2022: 18 · 2021: 9 · 2020: 17 · 2019: 17 · 2018: 14 · 2017: 13 · 2016: 11 · 2015: 12 · 2014: 12 · 2013: 4
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (tdm)
- Locations
- Molecular Neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Lume (Universidade Federal do Rio Grande do Sul) (submittedVersion, cc-by-nc-sa)
- Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- resveratrol, amyloid-beta 42, Alzheimer's disease, lipid-core nanocapsules, nanoparticle drug delivery, neuroprotection, learning and memory impairment, astrocyte activation, microglial activation, JNK, GSK3β, β-catenin, intracerebroventricular administration
- MeSH terms
- Glycogen Synthase Kinase 3 beta, Resveratrol, Animals, Astrocytes, Enzyme Activation, Hippocampus, Injections, Intraventricular, Lipids, Male, Memory Disorders, Stilbenes, Synapses, Tissue Distribution, Signal Transduction, Amyloid beta-Peptides, Rats, Wistar, Microglia, Neuroprotective Agents, Cytoprotection, Glycogen Synthase Kinase 3, JNK Mitogen-Activated Protein Kinases, beta Catenin, Rats, Nanocapsules, Protein Stability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
